ERBB2 and salivary gland cancer: To improve outcomes and efficacy of treatment of primary and/or metastatic parotid SCC, systematic studies involving larger series of HER2+ salivary gland cancers or stratification of patients to HER2-targeted therapies by alternative strategies are needed to determine the contribution of HER2 targeting on tumor response outcomes in parotid SCC and other salivary gland cancers (17).